Dicot Pharma AB
OM:DICOT Voorraadrapport
Marktkapitalisatie: SEK 434.9m
Dicot Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6 Dicot Pharma heeft een totaal eigen vermogen van SEK132.4M en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK140.8M en SEK8.4M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
Rente dekkingsratio n/a Contant SEK 130.40m Aandelen SEK 132.40m Totaal verplichtingen SEK 8.40m Totaal activa SEK 140.80m
Recente financiële gezondheidsupdates
Toon alle updates
Here's Why We're Not Too Worried About Dicot Pharma's (STO:DICOT) Cash Burn Situation Nov 12
Dicot Pharma Announces Initiation of Phase 2A Clinical Study Nov 08
New major risk - Shareholder dilution Nov 07
Independent Chairman of the Board recently bought kr51k worth of stock Sep 29
Dicot Pharma AB (publ) Provides an Operational Update Sep 17
Dicot Pharma AB to Report Q2, 2024 Results on Aug 23, 2024 Jul 25
Dicot Pharma Announces Clinical Trial Application for Phase 2A Trial Jul 08
Dicot Pharma AB to Report Q3, 2024 Results on Aug 01, 2024 Jul 04
Dicot Pharma AB Completes a Pre-IND Meeting with FDA Jul 02
Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs Jun 08
Dicot AB (publ) Announces Positive Safety and Improved Efficacy Results from Phase 1 Study Apr 24
We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate Apr 09
Dicot AB (publ) to Report Q1, 2024 Results on May 06, 2024 Apr 08
Dicot AB (publ) Announces Recruitment Completed in Dicot's Phase 1 Trial Mar 12
New major risk - Financial position Feb 28
Dicot AB (publ) to Report Fiscal Year 2023 Results on Feb 26, 2024 Jan 29
Dicot AB (publ) Presents Positive Results from the First Part of its Phase 1 Clinical Study Jan 23
Dicot Applies for Patent Covering New Manufacturing Technology Jan 11
We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully Dec 23
Dicot AB (publ) Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year Dec 15
Director exercised options to buy kr169k worth of stock. Nov 20
New minor risk - Share price stability Nov 17
Dicot AB, Annual General Meeting, May 06, 2024 Oct 28
Dicot AB Initiates Repeated Dosing in Phase I Study Oct 25
The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023 Oct 20
Dicot AB to Report Q3, 2023 Results on Oct 31, 2023 Oct 02
Dicot AB Applies for International Patent Protection Sep 27
Dicot AB Announces First Participants Dosed in Phase 1 Trial Sep 05
Dicot AB Applies for US Patent Aug 30
Dicot AB (publ) Announces Clinical Phase 1 Study Starts Aug 25
Dicot AB Receives Approval to Start Phase 1 Clinical Trial Aug 15
Dicot AB to Report Q2, 2023 Results on Aug 24, 2023 Jul 26
Director exercised options to buy kr194k worth of stock. Jun 21
New major risk - Share price stability Jun 20
Dicot AB (publ) Submits Application to Start Clinical Phase 1 Trial Jun 02
Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01 May 23
Dicot's Study Drug Arrives in Sweden May 18
Dicot AB Appoints Mats Silvander as New chief technical officer May 05
Dicot AB Study Results Presented at European Society for Sexual Medicine Feb 18
Dicot AB to Report Fiscal Year 2022 Results on Feb 27, 2023 Jan 29
No independent directors Nov 16
Dicot AB Announces That It's Latest Study of the Mechanism of Action of LIB-01 Assumed to Be the Next Generation of Potency Drugs Nov 16
Dicot AB Announces Successful First Regulatory Meeting for LIB-01 Nov 15 Dicot AB to Report Q3, 2022 Results on Nov 15, 2022 Oct 18
Dicot AB Reports Good Results from Preclinical Toxicology Studies Oct 12
Dicot AB to Report Q2, 2022 Results on Aug 25, 2022 Jul 28
Dicot AB Moves Forward with New Patent Application Jun 11
First quarter 2022 earnings released May 08
No independent directors Apr 27
Dicot AB Appoints Charlotta Gauffin as Chief Scientific Officer Apr 20
Dicot AB Announces Board Changes Apr 08 Dicot to Develop LIB-01 to an Oral Drug
Dicot AB Announces CEO Changes Apr 03 Dicot Announces CFO Changes, Effective March 7, 2022
Dicot Announces That the Results of Dicot's Drug Candidate Will Be Presented At the European Society for Sexual Medicine Dec 08
Dicot AB Announces Election of Eva Sjökvist Saers as the Chairman of Board, At the Extraordinary General Meeting Held on February 9, 2021 Feb 10
Dicot AB (publ) Broadens Testing of the Drug Candidate LIB-01 Feb 06
New 90-day low: kr0.94 Feb 02
Dicot Initiates Toxicology Studies Before Applying for Clinical Trials Jan 29
New 90-day low: kr0.99 Jan 12
New 90-day low: kr1.06 Dec 22
Dicot Ordinary Shares to Be Deleted from Other OTC Nov 27
New 90-day low: kr1.11 Nov 17
New 90-day low: kr1.33 Oct 20
Dicot AB Continues Studies with Pelvipharm to Generate Knowledge About Treatment Times, Doses and Libiguin's® Mechanism of Action Oct 13
Dicot AB Announces That Sustainable Supply of Raw Material Important to Dicot Oct 07
Dicot AB to Report Q2, 2020 Results on Aug 27, 2020 Sep 12
New 90-day high - kr2.45 Sep 12
Dicot AB to Report Q3, 2020 Results on Nov 23, 2020 Aug 31
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( SEK140.8M ) DICOT } overtreffen de korte termijn passiva ( SEK8.4M ).
Langlopende schulden: DICOT heeft geen langlopende schulden.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: DICOT is schuldenvrij.
Schuld verminderen: DICOT had 5 jaar geleden geen schulden.
Analyse van de cashflow Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: DICOT heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.
Voorspelling contante baan: DICOT heeft voldoende kasruimte voor 1.9 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 26.3 % per jaar.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
